A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

ClinicalTrials.gov ID: NCT06570798

Public ClinicalTrials.gov record NCT06570798. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 4, 2026, 2:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Open Label, Multicenter, Platform Trial to Assess the Safety, Tolerability, and Efficacy of Inebilizumab and Blinatumomab in Subjects With Autoimmune Diseases

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part A) and in adult participants with active refractory rheumatoid arthritis (RA) (Subprotocol C Part A). The trial will also assess the efficacy of SC blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part B and Subprotocol C Part B).

Study identification

NCT ID: NCT06570798
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Amgen; Industry
Enrollment: 220 participants

Conditions and interventions

Conditions

Interventions

Inebilizumab Drug
Blinatumomab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 15, 2025
Primary completion: Aug 5, 2028
Completion: Aug 5, 2028
Last update posted: Aug 20, 2026

2025 – 2028

United States locations

U.S. sites: 18
U.S. states: 10
U.S. cities: 16

Facility	City	State	ZIP	Site status
HonorHealth Research and Innovation Institute	Scottsdale	Arizona	85258	Recruiting
University of Colorado	Aurora	Colorado	80045	Recruiting
Vida Research Center	Hialeah	Florida	33010	Terminated
Homestead Associates In Research Inc	Homestead	Florida	33033	Terminated
Vitaly Clinical Research	Miami	Florida	33125	Terminated
Bioresearch Partner Coral Terrace	South Miami	Florida	33143	Recruiting
University Medical Center New Orleans	New Orleans	Louisiana	70112	Recruiting
Massachusetts General Hospital	Boston	Massachusetts	02114	Recruiting
Mayo Clinic	Rochester	Minnesota	55905	Recruiting
Northwell Health	Great Neck	New York	11021	Recruiting
Westchester Medical Center	Hawthorne	New York	10532	Completed
Columbia University Medical Center	New York	New York	10032	Recruiting
University of Rochester Medical Center	Rochester	New York	14642	Recruiting
MetroHealth Medical Center	Cleveland	Ohio	44109	Recruiting
The Metro Health System Main Campus	Cleveland	Ohio	44109	Recruiting
Cleveland Clinic Foundation	Cleveland	Ohio	44195	Recruiting
Prolato Clinical Research Center	Houston	Texas	77054	Completed
Seattle Rheumatology Associates	Seattle	Washington	98104	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06570798, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 20, 2026 · Synced Sep 4, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06570798 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →